Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmicals宣佈將提供該公司正在德國柏林進行的帕拉西司朗與Cdk4/6抑制劑Ribociclib聯合使用的1b/2期臨床研究的新臨床數據
Olema Pharmaceuticals Announced That It Will Present New Clinical Data From The Company's Ongoing Phase 1b/2 Clinical Study Of Palazestrant In Combination With Cdk4/6 Inhibitor Ribociclib In Berlin, Germany
Olema Pharmicals宣佈將提供該公司正在德國柏林進行的帕拉西司朗與Cdk4/6抑制劑Ribociclib聯合使用的1b/2期臨床研究的新臨床數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。